Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Multi-center study shows WATS3D biopsy increases detection of esophageal pre-cancer by 60% following endoscopic ablation of Barrett’s Esophagus

CDx Diagnostics announced today new clinical data from a multi-center study demonstrating the utility of the WATS3D biopsy for post-ablation surveillance of Barrett’s esophagus and esophageal dysplasia...

18 May 2015

Multi-center study shows WATS3D biopsy increases detection of esophageal pre-cancer by 60% following endoscopic ablation of Barrett’s Esophagus

18 May 2015

Studies support use of ThyraMIR and ThyGenX to improve detection of benign/malignant thyroid nodules

Data will be presented at both Digestive Disease Week (DDW) and the American Association of Clinical Endocrinologists (AACE) annual medical meetings.

18 May 2015

Long-term survivors of esophageal cancer still face continued risks, study finds

Patients with esophageal cancer who survive 5 years after undergoing surgery might breathe a sigh of relief and become complacent about continued monitoring. In fact, there is little published information on the outcome of patients with locally advanced esophageal cancer (LAEC) who survive beyond the 5-year mark.

30 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

Incidence of esophageal cancer linked to GERD rises six-fold in recent decades

Esophageal cancer is one of the fastest-growing and deadliest cancers in the U.S. According to the American Cancer Society, an estimated 17,000 new cases of esophageal cancer will be diagnosed in 2015. Incidence of adenocarcinoma, a type of esophageal cancer linked to GERD (gastroesophageal reflux disease) has risen six-fold in recent decades.

21 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Scientists reveal three major subsets of KRAS-mutant LUAC

Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.

20 Apr 2015

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

20 Apr 2015

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada.

1 Apr 2015

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth, a global leader in engineered cell therapies, today announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich.

27 Mar 2015

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.

25 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

BUSM researchers discover genes involved in formation of lung tumors

The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung interstitial disease, post-natal respiratory distress and lung cancer.

3 Mar 2015

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma.

27 Feb 2015

Rare and classic EGFR mutations have different impacts on NSCLC outcome

Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common "classical" EGFR mutations.

12 Feb 2015

St. John Hospital first in Michigan to offer new alternative treatment for acid reflux disease

St. John Hospital is among the first in the state and the only site in southeast Michigan to offer a new alternative treatment for patients with acid reflux disease.

10 Feb 2015

New study provides better understanding of how stem cells give rise to tumors

Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a precise stem cell signaling process that can lead to intestinal tumors if disrupted. The findings add to our understanding of how stem cells give rise to tumors and identify specific stem cell molecules that may be targeted to prevent the onset, progression, and recurrence of intestinal cancers.

6 Feb 2015

Researchers develop optimised PSA screening programme for prostate cancer

As an indicator of prostate cancer, the PSA test is regarded in urology as highly controversial since it is not always unequivocal. A team of researchers from the Comprehensive Cancer Center at the MedUni Vienna and Vienna General Hospital has now developed a programme that compensates the shortfalls of PSA screening with methods from personalised medicine. As a result, prostate cancer screening is able to reach a new level of quality.

4 Feb 2015

Adenocarcinoma News and Research

Further Reading

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Multi-center study shows WATS3D biopsy increases detection of esophageal pre-cancer by 60% following endoscopic ablation of Barrett’s Esophagus

Multi-center study shows WATS3D biopsy increases detection of esophageal pre-cancer by 60% following endoscopic ablation of Barrett’s Esophagus

Studies support use of ThyraMIR and ThyGenX to improve detection of benign/malignant thyroid nodules

Long-term survivors of esophageal cancer still face continued risks, study finds

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Incidence of esophageal cancer linked to GERD rises six-fold in recent decades

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Scientists reveal three major subsets of KRAS-mutant LUAC

Some lung cancer patients can benefit from melanoma drugs

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

BUSM researchers discover genes involved in formation of lung tumors

Targeting stroma could potentially extend survival of pancreatic cancer patients

Rare and classic EGFR mutations have different impacts on NSCLC outcome

St. John Hospital first in Michigan to offer new alternative treatment for acid reflux disease

New study provides better understanding of how stem cells give rise to tumors

Researchers develop optimised PSA screening programme for prostate cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News